https://doi.org/10.48047/AFJBS.6.12.2024.2967-2983

African Journal of Biological Sciences

Journal homepage: http://www.afjbs.com

Research Paper Open Access

RECOMBINANT PROTEIN EXPRESSION: RECENT ADVANCEMENTS

VIRENDRA S. GOMASE*[1], ABHAY D. SAKHARE[2],SANJAY N. VASU[3], ANDPAVAN G. KAKADE[4]

[1]S.P. Mandali's Prin. L. N. Welingkar Institute of Management Development & Research, Mumbai, 400019, India*Email- viren.gomase1@gmail.com

[2]Department of Pharmaceutics, Anuradha College of Pharmacy, Chikhli, 443201, Sant Gadge Baba Amravati University, Amravati, 444602, MS, IndiaEmail- abhaykumarsakhare@gmail.com

[3]Mahatma Phule Pharmacy College, Babhulgaon, Akola, 444104, Sant Gadge Baba Amaravati University, Amaravati, 444602, MS, IndiaEmail- vasusanjay022@gmail.com

[4]Department of Pharmaceutics, Jayawantrao Sawant College of Pharmacy and Research, Savitribai Phule Pune University, Pune, 411028, IndiaEmail- kakadepavan8989@gmail.com

Corresponding Author: VIRENDRA S. GOMASE email: viren.gomase1@gmail.com

Article History
Volume 6, Issue 12, 2024
Received Date: 20May 2024
Acceptance Date: 28 June 2024
Doi:
10.48047/AFJBS.6.12.2024.2967-2983

Abstract - The technique known as "recombinant protein expression" uses modified host cells to generate high amounts of a particular protein. Because this technology may be used to synthesize proteins that are hard to obtain in big quantities from natural sources, it is vital for industry, research, and medicine. The biotechnology technique of recombinant protein expression is useful and effective. Improvements in genetic engineering, synthetic biology, and bioinformatics are opening the door to more affordable and effective production methods, even though there are still problems to be overcome. Recombinant protein expression will surely find more uses and have a greater impact across a wide range of industries as long as cutting-edge methods and host systems are continuously developed.

Keywords: Gene Cloning, Vector Construction, Transformation, Expression of Protein, Harvesting

Introduction

Large-scale production of targeted proteins using modified host cells is possible through the technique of recombinant protein expression. When it comes to developing proteins that are hard to come by in significant quantities from natural sources, this method is crucial for research, healthcare, and business. One effective and multipurpose tool in biotechnology is recombinant protein expression. The fields of genetic engineering, synthetic biology, and bioinformatics are making strides toward more productive and affordable production systems, although still having obstacles to overcome. No doubt, the applications and effect of recombinant protein expression in a variety of sectors will grow as new methodologies and host systems continue to be developed [1-4]. Here's a detailed overview of the process:

A. Key Steps in Recombinant Protein Expression

1.Gene Cloning

- Gene Identification: Identify the gene encoding the protein of interest.
- Gene Synthesis or PCR Amplification: Obtain the gene sequence by synthesizing it chemically or amplifying it using PCR [5].

2.Vector Construction

- Plasmid Vector: Insert the gene into a plasmid vector, which often contains regulatory elements such as promoters, enhancers, and selectable markers to facilitate expression.
- Restriction Enzymes and Ligation: Once the plasmid and the gene have been cut with restriction enzymes, ligate the gene into the plasmid [6].

3.Transformation

- Host Cell Selection: Choose an appropriate host cell (e.g., bacteria like *E. coli*, yeast, insect cells, or mammalian cells).
- Introduction of Plasmid: Introduce the recombinant plasmid into the host cells through methods like heat shock, electroporation, or chemical transformation.

4.Expression of Protein

- Culture Conditions: Grow the transformed host cells under conditions that promote protein expression (e.g., temperature, induction with IPTG in the case of *E. coli*).
- Optimization: Optimize factors such as temperature, pH, and nutrient concentration for maximum protein production [7].

5.Harvesting

- Cell Lysis: Harvest the cells and lyse them to release the protein. Methods for lysis include sonication, enzymatic treatment, or mechanical disruption.
- Purification: Use chromatography techniques (e.g., affinity, ion-exchange, size-exclusion) to purify the recombinant protein from the cell lysate [8].

6.Verification and Characterization

- SDS-PAGE and Western Blot: Use SDS-PAGE to analyze protein purity and Western blotting to confirm the identity of the protein.
- Functional Assays: Conduct functional assays to ensure the protein retains its biological activity [9].

B. Host Systems for Recombinant Protein Expression

1.Bacterial Systems (e.g., *E. coli*)

- Advantages: Rapid growth, high yield, cost-effective.
- Disadvantages: Limited post-translational modifications, possible formation of inclusion bodies [10].

2.Yeast Systems (e.g., *Saccharomyces cerevisiae*)

- Advantages: Eukaryotic system, capable of post-translational modifications, relatively easy to culture.
- Disadvantages: Glycosylation patterns may differ from those in higher eukaryotes [11].

3.Insect Cell Systems (e.g., *Baculovirus system*)

- Advantages: High-level expression, suitable for complex proteins [12].
- Disadvantages: More complex and costly than bacterial systems.

4.Mammalian Cell Systems (e.g., CHO cells)

- Advantages: Proper folding and post-translational modifications, suitable for therapeutic proteins [13].
- Disadvantages: High cost, slower growth, complex culture conditions.

C. Applications of Recombinant Protein Expression

The large-scale manufacturing of proteins required for industry, research, agriculture, and therapies has been made possible by recombinant protein expression, which has revolutionized several fields. Recombinant protein expression is a key biotechnology tool that will become even more important as technology develops because of its increased efficiency, scalability, and variety of uses. Because recombinant protein expression makes it possible to produce proteins on a wide scale that are vital for industry, research, agriculture, and therapies, it has revolutionized many fields.

The efficiency, scalability, and variety of uses for recombinant protein expression will increase with technological advancement, solidifying its position as a key biotechnology tool.Recombinant protein expression is now a vital instrument for developments in a wide range of industries, including business, agriculture, research, medicine, and more. Here, we explore the different uses for this potent technology. In many domains, including agriculture, industry, research, and health, recombinant protein expression has emerged as a crucial tool for solving problems and advancing progress. In this article, we explore the several uses for this potent technology [14,15].Applications of Recombinant Protein Expression:

1. Therapeutics

1.1. Production of Biopharmaceuticals

- Insulin: Recombinant human insulin was the first biopharmaceutical approved for therapeutic use, revolutionizing diabetes treatment. Produced in *E. coli* or yeast, it is now a mainstay in managing diabetes mellitus [16,17].
- Monoclonal Antibodies (mAbs): These are used in treating cancers, autoimmune diseases, and infectious diseases. Examples include trastuzumab (Herceptin) for breast cancer and adalimumab (Humira) for rheumatoid arthritis.
- Vaccines: Recombinant protein technology enables the production of safe and effective vaccines, such as the hepatitis B vaccine and the more recent HPV vaccine.

1.2. Enzyme Replacement Therapies

- Gaucher's Disease: Recombinant glucocerebrosidase is used to treat this lysosomal storage disorder [18].
- Cystic Fibrosis: Recombinant DNase is used to break down mucus in the lungs of cystic fibrosis patients [19].

2. Research

2.1. Structural Biology

- Protein Structure Determination: Three-dimensional structures can be ascertained by using recombinant proteins in cryo-electron microscopy, NMR spectroscopy, and X-ray crystallography. Understanding protein structures aids in drug design and functional analysis [20].

2.2. Functional Studies

- Protein-Protein Interactions: Expressing recombinant proteins allows for the study of interactions, which is crucial for understanding cellular processes and signaling pathways.
- Gene Regulation and Expression: Recombinant proteins can be used to study gene regulation mechanisms, transcription factors, and epigenetic modifications [21].

3. Industrial Applications

3.1. Enzymes for Industrial Processes

- Detergents: Proteases, lipases, and amylases are used in laundry detergents to break down stains and improve cleaning efficiency.
- Biofuels: Enzymes such as cellulases and hemicellulases are employed in the production of bioethanol from plant biomass.
- Food Processing: Recombinant enzymes like rennet (chymosin) are used in cheese production, and amylases are used in baking and brewing [22,23].

3.2. Bioremediation

- Pollutant Degradation: Recombinant microorganisms are engineered to produce enzymes capable of breaking down environmental pollutants, such as oil spills and heavy metals [24].

4. Agriculture

4.1. Genetically Modified Crops

- Pest Resistance: Crops expressing *Bacillus thuringiensis* (Bt) toxin are resistant to insect pests, reducing the need for chemical pesticides [25,26].
- Herbicide Tolerance: Crops engineered to be resistant to herbicides like glyphosate allow for more efficient weed control.
- Nutritional Enhancement: Golden Rice is an example of a genetically modified crop enriched with provitamin A to combat vitamin A deficiency in developing countries [27].

4.2. Veterinary Medicine

- Animal Health: Recombinant vaccines and therapeutics are used to prevent and treat diseases in livestock, improving animal health and productivity [28].

5. Diagnostics

5.1. Diagnostic Reagents

- Enzymes and Antigens: Recombinant enzymes and antigens are used in diagnostic tests, such as ELISA and PCR, for detecting diseases like HIV, hepatitis, and COVID-19.
- Biosensors: Recombinant proteins are used in biosensors for real-time detection of various analytes, including glucose monitoring in diabetes management [29,30].

5.2. Imaging and Tracing

- Fluorescent Proteins: GFP and other fluorescent proteins are used as markers in live-cell imaging to study cellular processes in real time.
- Radio-labeled Proteins: Used in diagnostic imaging techniques like PET and SPECT to visualize and quantify biological processes *in vivo*[31,32].

D. Challenges in Recombinant Protein Expression

Recombinant protein expression is a powerful technology with broad applications, but it comes with several challenges that can affect the efficiency, yield, and quality of the expressed protein. Understanding these challenges is crucial for developing effective strategies to overcome them.

1. Protein Solubility

1.1. Inclusion Bodies

- Formation: Many recombinant proteins expressed in bacterial systems, especially in *E. coli*, tend to form insoluble aggregates called inclusion bodies.

- Resolution: Solubilizing and refolding proteins from inclusion bodies is often complex and inefficient, which can result in loss of protein activity [33].

1.2. Aggregation

- Mechanism: Overexpression of recombinant proteins can overwhelm the host cell's folding machinery, leading to aggregation (ex. C43(DE3), C41(DE3), and BL21(DE3).
- Mitigation: Co-expression of molecular chaperones, optimizing expression conditions (e.g., temperature, induction time), and using fusion tags can help improve solubility [34].

2. Post-Translational Modifications (PTMs)

2.1. Limited PTMs in Prokaryotic Systems

- *E. coli*: Lacks the machinery for many eukaryotic PTMs, such as glycosylation, phosphorylation, and proper disulfide bond formation.
- Impact: Proteins requiring these modifications may not be functional or correctly folded when expressed in bacterial systems [35].

2.2. Alternative Hosts

- Yeast, Insect, and Mammalian Cells: These hosts can perform more complex PTMs, but they come with higher costs, slower growth rates, and more complex culture requirements.
- Glycosylation Differences: Even in eukaryotic hosts, glycosylation patterns can differ from those in humans, potentially affecting protein function [36].

3. Yield Optimization

3.1. Toxicity to Host Cells

- High Expression Levels: Overexpression of recombinant proteins can be toxic to host cells, leading to cell death and reduced yields.
- Solutions: Tuning the expression levels using inducible promoters, optimizing culture conditions, and using host strains with enhanced tolerance to recombinant protein expression [37].

3.2. Metabolic Burden

- Resource Allocation: The production of recombinant proteins can divert resources from essential cellular processes, stressing the host cells.
- Engineering Hosts: Developing host strains with optimized metabolic pathways to better support high-level protein production [38].

4. Protein Purification

4.1. Downstream Processing

- Complexity: Purification of recombinant proteins often involves multiple steps, which can be time-consuming and costly.
- Yield Loss: Each purification step can result in loss of protein yield, affecting the overall efficiency of the process [39].

4.2. Tag Removal

- Fusion Tags: While fusion tags facilitate purification, they may need to be removed for the protein to be functional or suitable for therapeutic use.
- Protease Specificity: Ensuring the protease used for tag removal does not cleave the protein of interest or cause unwanted side effects [40].

5. Host System Limitations

5.1. *E. coli*

- Advantages: Rapid growth, cost-effective, easy genetic manipulation.
- Disadvantages: Limited PTMs, issues with protein solubility, potential endotoxin contamination in therapeutic applications.

5.2. Yeast

- Advantages: Capable of some PTMs, relatively easy to culture.
- Disadvantages: Different glycosylation patterns, slower growth than bacteria.

5.3. Insect Cells

- Advantages: High-level expression, suitable for complex proteins.
- Disadvantages: More expensive, complex culture conditions.

5.4. Mammalian Cells

- Advantages: Proper folding and PTMs, ideal for therapeutic proteins.
- Disadvantages: High cost, slower growth, stringent regulatory requirements [41,42].

6. Regulatory and Quality Control Issues

6.1. Consistency and Reproducibility

- Batch-to-Batch Variation: Ensuring consistent quality and yield across different production batches is challenging.
- Quality Control: Implementing rigorous quality control measures to ensure the purity, potency, and safety of the recombinant proteins, especially for therapeutic applications.

6.2. Regulatory Compliance

- GMP Standards: Adhering to Good Manufacturing Practices (GMP) is essential for the production of therapeutic proteins, requiring strict protocols and documentation.
- Regulatory Approval: Obtaining regulatory approval for recombinant proteins involves extensive testing and validation, which can be time-consuming and costly [43-46].

E. Strategies to Overcome Challenges

- Codon Optimization: Tailoring the gene sequence to match the host's codon usage can improve translation efficiency and protein yield.Modifying the gene sequence to match the codon usage preferences of the host organism can significantly improve protein expression [47].
- Fusion Proteins and Tags: Utilizing fusion partners and tags to enhance solubility and simplify purification.Adding tags such as His-tags or GST-tags can simplify protein purification and improve yield [48].
- Chaperones and Folding Aids: Co-expressing molecular chaperones to aid in proper protein folding.Co-expressing molecular chaperones or using additives can help in proper protein folding and solubility [49].
- Synthetic Biology: Engineering host cells with optimized pathways and enhanced capabilities for protein production [50].
- Advanced Purification Techniques: Developing more efficient and scalable purification methods to improve yield and reduce costs [51].
- Cell-Free Systems: Using cell-free expression systems to bypass some of the limitations of living host cells, offering rapid and scalable protein production [52].
- Promoter Selection: Choosing strong and regulatable promoters can enhance transcription efficiency [53].
- Media Optimization: Adjusting the composition of the growth media, including carbon and nitrogen sources, can enhance cell growth and protein production.

Although recombinant protein expression is an effective and flexible technology, there are a number of issues that must be resolved in order to fully realize its potential. Through a comprehensive understanding of these obstacles and the application of inventive tactics, scientists can improve protein yield, functioning, and overall process efficiency. Further developments in genetic engineering, synthetic biology, and molecular biology will enhance the versatility and durability of recombinant protein expression across multiple domains. Recombinant protein expression is an effective and flexible tool, but in order to fully realize its potential, a number of issues must be resolved. Researchers can improve protein yield, functionality, and overall process efficiency by comprehending these issues and putting creative solutions into practice. The robustness and generalizability of recombinant protein expression will be further enhanced by ongoing developments in molecular biology, genetic engineering, and synthetic biology.

F. Recent Advancements and Future Directions

Growing knowledge of molecular biology and advances in biotechnology are driving the ongoing evolution of recombinant protein expression. These developments seek to solve current issues and pave the way for novel uses of recombinant proteins. This section examines future directions in this rapidly evolving discipline and highlights current advances.Advances in biotechnology and a greater comprehension of molecular biology are driving the ongoing evolution of recombinant protein production. These developments are meant to solve current problems and developing new opportunities for the use of recombinant proteins. This section examines future directions and discusses recent developments in this rapidly evolving discipline.

I. Recent Advancements

1. Synthetic Biology and Genetic Engineering

1.1. Synthetic Biology

- Gene Synthesis and Assembly: The expense and time needed to develop and assemble synthetic genes have drastically decreased because to advances in gene synthesis technology, making it possible to precisely design coding sequences that are optimized for expression in a variety of host systems [54-56].
- Modular Cloning Systems: Various gene elements, regulatory sequences, and pathways can be integrated more easily and effectively into complex genomic constructions thanks to systems like Gibson Assembly and Golden Gate Assembly [57].

1.2. Genome Editing

- CRISPR/Cas9: In prokaryotes, the CRISPR system—clustered regularly interspaced short palindromic repeats—offers adaptive immunity against plasmids and phages. Genome editing has been transformed by the CRISPR/Cas9 system, which makes it possible to precisely alter host cell genomes to improve protein expression, stability, and functioning. Using this approach, harmful regulatory elements can be eliminated, advantageous mutations can be inserted, or artificial pathways can be integrated [58].
- TALENs and ZFNs: Zinc finger nucleases (ZFNs) and transcription activator-like effector nucleases (TALENs) are also employed for targeted genome changes, providing further genetic engineering tools [59].

2. Advanced Expression Systems

2.1. Cell-Free Protein Synthesis (CFPS)

- Advantages: Rapid protein synthesis is made possible by CFPS systems, which get over the restrictions imposed by living cells on metabolism and cell viability. This approach is very helpful for hazardous proteins, high-throughput screening, and proteins that need non-natural amino acids.
- Applications: Applications of synthetic biology using CFPS include the synthesis of enzymes, medicinal proteins, and research on protein engineering [60].

2.2. Optimized Host Systems

- Engineered Bacterial Strains: *E. coli* strains that have been modified to increase tolerance to hazardous proteins, decrease protease activity, and improve protein folding have been reported. Strains that contain molecular chaperones or have been altered to maximize codon use are two examples.
- Yeast and Fungal Systems: *Pichia pastoris* and *Saccharomyces cerevisiae* are examples of advanced yeast expression systems that have increased yields and made more complicated post-translational modifications possible. Additionally, fungi systems such as Aspergillus are being refined for the manufacture of industrial enzymes.
- Insect and Mammalian Cells: Advancements in the Baculovirus expression method and mammalian cell lines, such as HEK293 and CHO cells, have resulted in superior post-translational modifications and increased expression levels, rendering them perfect for the production of therapeutic proteins [61].

3. High-Throughput Screening and Automation

3.1. Automated Platforms

- Robotics and Automation: The throughput, uniformity, and reproducibility of protein expression and purification processes have enhanced with the integration of robotics and automation. Workflows for cloning, transformation, expression screening, and purification are streamlined by automated systems [62].
- Microfluidics: Miniaturized and parallelized protein expression and screening are made possible by microfluidic devices, which lowers reagent use and speeds up the process of determining the best expression conditions [63-65].

3.2. High-Throughput Screening

- Library Screening: High-throughput approaches are used to screen large libraries of gene variations, expression constructs, and host strains in order to determine the best conditions for protein expression. This method expedites the process of finding high-yield, high-quality expression systems [66,67].

4. Enhanced Purification and Characterization Techniques

4.1. Chromatography Innovations

- Affinity Tags and Resins: The effectiveness and selectivity of protein purification have increased with the development of novel affinity tags and resins. Certain tags, including as FLAG-tag, Halo-tag, and Strep-tag, provide special benefits for functional research and purification.
- Single-Step Purification: Modern chromatography methods, such as single-step and multimodal purification systems, cut down on the complexity and time needed to purify proteins [68-70].

4.2. Analytical Tools

- Mass Spectrometry: Recombinant proteins may be thoroughly characterized, including post-translational changes and protein-protein interactions, thanks to high-resolution mass spectrometry.

- Biophysical Methods: Protein folding, stability, and binding interactions can be better understood by using methods like surface plasmon resonance (SPR), differential scanning calorimetry (DSC), and circular dichroism (CD) [71].

II. Future Directions

1. Synthetic Biology and Metabolic Engineering

1.1. De Novo Pathway Design

- Custom Biosynthetic Pathways: Developing synthetic pathways to produce natural chemicals and complicated proteins. Developing de novo metabolic pathways that are not found in nature is one way to do this, as it facilitates the synthesis of novel chemicals and biotherapeutics [72].

1.2. Orthogonal Systems

- Non-Natural Amino Acids: Development of orthogonal translation systems that enhance the functional diversity and potential of recombinant proteins by incorporating non-natural amino acids into proteins.
- Synthetic Organelles: Developing synthetic organelles inside of cells to divide and streamline particular biosynthetic processes, improving the expression and performance of proteins.

2. Host System Innovations

2.1. Synthetic Microorganisms

- Minimal Cells: Simplifying cells and their genomes to make them ideal for high-efficiency protein expression. Because these artificial creatures wouldn't have any unnecessary genes, their metabolic load would be lower and their yields would increase.
- Probiotic Hosts: Developing probiotic microbes that can manufacture therapeutic proteins inside the human body to provide new ways for biologic delivery.

2.2. Mammalian Systems

- Enhanced CHO Cells: Further CHO cell engineering to raise protein outputs, lower manufacturing costs, and strengthen glycosylation capabilities. This involves enhancing the conditions of the bioreactor and the medium compositions.
- Stem Cells: Recombinant proteins with native-like post-translational modifications can be produced using stem cells, especially for regenerative medicine and customized treatments [73-75].

3. Environmental and Sustainable Applications

3.1. Bioremediation

- Environmental Engineering: Developing recombinant microbes with the ability to break down plastics, heavy metals, and contaminants in order to support sustainability and environmental cleaning initiatives.
- Synthetic Ecology: Assembling collaborative microbial consortia to carry out intricate bioremediation operations in a manner reminiscent of natural ecosystems [76-78].

3.2. Sustainable Production

- Bio-Based Materials: Utilizing recombinant protein expression systems to produce bio-based products and bioplastics, lowering dependency on petrochemicals, and advancing environmentally friendly manufacturing techniques.
- Agricultural Biotechnology: Enhancing crop yields, stress resilience, and nutrient uptake in crops and soil microorganisms to promote sustainable agriculture and food security [79].

4. Therapeutic and Diagnostic Innovations

4.1. Personalized Medicine

- Patient-Specific Therapies: Manufacturing synthetic proteins customized to each patient's genetic profile, allowing for individualized approaches to treating genetic abnormalities and diseases including cancer.
- On-Demand Biologics: Constructing scalable and transportable systems for the on-demand synthesis of therapeutic proteins to enable quick reaction to epidemics and medical emergencies[80-83].

4.2. Advanced Diagnostics

- Next-Generation Biosensors: Developing recombinant protein-based biosensors that are extremely sensitive and selective for monitoring health conditions, environmental monitoring, and early disease detection [84-86].
- Point-of-Care Diagnostics: Developing recombinant protein-based portable and user-friendly diagnostic tools that enable quick and precise illness diagnosis at the point of care [87-90].

Summary

Advancements in synthetic biology, genetic engineering, and biotechnology are driving rapid growth in the field of recombinant protein expression. These advancements are addressing pressing problems and expanding the potential applications of recombinant proteins. Rapid breakthroughs in synthetic biology, genetic engineering, and technology are driving the field of recombinant protein expression. These advancements are expanding the potential applications of recombinant proteins by addressing present problems. A key technology for business, research, health, and environmental sustainability is recombinant protein expression. Technology's efficiency, versatility, and scalability will all grow as it develops. There is a bright future for recombinant protein expression, one that might significantly

expand scientific understanding, promote sustainable development, and enhance human health. As technology advances, recombinant protein expression will become more effective, scalable, and valuable in a greater variety of applications, increasing its importance as a crucial technology in business, research, health, and environmental sustainability. In the future, recombinant protein expression holds great promise for advancing scientific understanding, human health, and sustainable development.

Acknowledgement / Funding: Author is thankful to S.P. Mandali's Prin. L. N. Welingkar Institute of Management Development & Research, Mumbai, 400019, India

Author Contributions: Sole author

Conflict of Interest: No Conflict of Interest

References

[1] Tripathi NK, Shrivastava A. Recent Developments in Bioprocessing of Recombinant Proteins: Expression Hosts and Process Development. Front BioengBiotechnol. 2019 Dec 20;7:420. doi: 10.3389/fbioe.2019.00420.
[2] Chauhan S, Khasa YP. Challenges and Opportunities in the Process Development of Chimeric Vaccines. Vaccines (Basel). 2023 Dec 8;11(12):1828. doi: 10.3390/vaccines11121828.
[3] Tripathi NK, Shrivastava A. Recent Developments in Bioprocessing of Recombinant Proteins: Expression Hosts and Process Development. Front BioengBiotechnol. 2019 Dec 20;7:420. doi: 10.3389/fbioe.2019.00420.
[4] Gomase VS, Kale KV, Tagore S, Hatture SR. Proteomics: technologies for protein analysis. Curr Drug Metab. 2008 Mar;9(3):213-20. doi: 10.2174/138920008783884740.
[5] Gomase VS, Tagore S. Epigenomics. Curr Drug Metab. 2008 Mar;9(3):232-7. doi: 10.2174/138920008783884821.
[6] Nora LC, Westmann CA, Martins-Santana L, Alves LF, Monteiro LMO, Guazzaroni ME, Silva-Rocha R. The art of vector engineering: towards the construction of next-generation genetic tools. MicrobBiotechnol. 2019 Jan;12(1):125-147. doi: 10.1111/1751-7915.13318.
[7] Ghosh A, Yang C, Lloyd K, Meijers R. High-Throughput Protein Expression Screening of Cell-Surface Protein Ectodomains. Methods Mol Biol. 2024;2810:301-316. doi: 10.1007/978-1-0716-3878-1_19.
[8] Pastor AR, Ramírez OT, Palomares LA. Construction of Recombinant Baculoviruses. Methods Mol Biol. 2024;2829:13-20. doi: 10.1007/978-1-0716-3961-0_2.
[9] Chen R. Bacterial expression systems for recombinant protein production: E. coli and beyond. Biotechnol Adv. 2012 Sep-Oct;30(5):1102-7. doi: 10.1016/j.biotechadv.2011.09.013.
[10] Oliveira C, Domingues L. Guidelines to reach high-quality purified recombinant proteins. Appl MicrobiolBiotechnol. 2018 Jan;102(1):81-92. doi: 10.1007/s00253-017-8623-8.
[11] Mattanovich D, Branduardi P, Dato L, Gasser B, Sauer M, Porro D. Recombinant protein production in yeasts. Methods Mol Biol. 2012;824:329-58. doi: 10.1007/978-1-61779-433-9_17.

[12] Irons SL, Chambers AC, Lissina O, King LA, Possee RD. Protein Production Using the Baculovirus Expression System. Curr Protoc Protein Sci. 2018 Feb 21;91:5.5.1-5.5.22. doi: 10.1002/cpps.45.
[13] Guo X, Wang C, Wang TY. Chromatin-modifying elements for recombinant protein production in mammalian cell systems. Crit Rev Biotechnol. 2020 Nov;40(7):1035-1043. doi: 10.1080/07388551.2020.1805401.

[14] 14 Andersen DC, Krummen L. Recombinant protein expression for therapeutic applications. Curr OpinBiotechnol. 2002 Apr;13(2):117-23. doi: 10.1016/s0958-1669(02)00300-2.
[15] Kumar V, Barwal A, Sharma N, Mir DS, Kumar P, Kumar V. Therapeutic proteins: developments, progress, challenges, and future perspectives. 3 Biotech. 2024 Apr;14(4):112. doi: 10.1007/s13205-024-03958-z.
[16] Baeshen MN, Al-Hejin AM, Bora RS, Ahmed MM, Ramadan HA, Saini KS, Baeshen NA, Redwan EM. Production of Biopharmaceuticals in E. coli: Current Scenario and Future Perspectives. J MicrobiolBiotechnol. 2015 Jul;25(7):953-62. doi: 10.4014/jmb.1412.12079.
[17] McElwain L, Phair K, Kealey C, Brady D. Current trends in biopharmaceuticals production in Escherichia coli. Biotechnol Lett. 2022 Aug;44(8):917-931. doi: 10.1007/s10529-022-03276-5.
[18] Zhang Z, Liu D, Yu Z, Xiao Z, Zhou K, Li B. Gaucher Disease Coexisting with Cytomegalovirus Infection: A Rare Presentation in an Infant. Am J Case Rep. 2024 Mar 21;25:e943398. doi: 10.12659/AJCR.943398.
[19] Lauková L, Konečná B, Janovičová Ľ, Vlková B, Celec P. Deoxyribonucleases and Their Applications in Biomedicine. Biomolecules. 2020 Jul 11;10(7):1036. doi: 10.3390/biom10071036.
[20] García-Nafría J, Tate CG. Structure determination of GPCRs: cryo-EM compared with X-ray crystallography. Biochem Soc Trans. 2021 Nov 1;49(5):2345-2355. doi: 10.1042/BST20210431.
[21] Pope SD, Medzhitov R. Emerging Principles of Gene Expression Programs and Their Regulation. Mol Cell. 2018 Aug 2;71(3):389-397. doi: 10.1016/j.molcel.2018.07.017.
[22] Patel N, Rai D, Shivam, Shahane S, Mishra U. Lipases: Sources, Production, Purification, and Applications. Recent Pat Biotechnol. 2019;13(1):45-56. doi: 10.2174/1872208312666181029093333. PMID: 30370868.
[23] Ali S, Khan SA, Hamayun M, Lee IJ. The Recent Advances in the Utility of Microbial Lipases: A Review. Microorganisms. 2023 Feb 17;11(2):510. doi: 10.3390/microorganisms11020510.
[24] Eskandari A, Leow TC, Rahman MBA, Oslan SN. Recent insight into the advances and prospects of microbial lipases and their potential applications in industry. Int Microbiol. 2024 Mar 15. doi: 10.1007/s10123-024-00498-7.
[25] Jouzani GS, Valijanian E, Sharafi R. Bacillus thuringiensis: a successful insecticide with new environmental features and tidings. Appl MicrobiolBiotechnol. 2017 Apr;101(7):2691-2711. doi: 10.1007/s00253-017-8175-y.
[26] Kamle S, Ali S. Genetically modified crops: detection strategies and biosafety issues. Gene. 2013 Jun 15;522(2):123-32. doi: 10.1016/j.gene.2013.03.107.
[27] Raman R. The impact of Genetically Modified (GM) crops in modern agriculture: A review. GM Crops Food. 2017 Oct 2;8(4):195-208. doi: 10.1080/21645698.2017.1413522.

[28] Hein R, Koopman R, García M, Armour N, Dunn JR, Barbosa T, Martinez A. Review of Poultry Recombinant Vector Vaccines. Avian Dis. 2021 Sep;65(3):438-452. doi: 10.1637/0005-2086-65.3.438.
[29] Gallagher S, Winston SE, Fuller SA, Hurrell JG. Immunoblotting and immunodetection. Curr Protoc Cell Biol. 2011 Sep;Chapter 6:Unit6.2. doi: 10.1002/0471143030.cb0602s52.
[30] Ni D, Xu P, Gallagher S. Immunoblotting and Immunodetection. Curr Protoc Cell Biol. 2017 Mar 3;74:6.2.1-6.2.37. doi: 10.1002/cpcb.18.
[31] Zhang C, Wei ZH, Ye BC. Imaging and tracing of intracellular metabolites utilizing genetically encoded fluorescent biosensors. Biotechnol J. 2013 Nov;8(11):1280-91. doi: 10.1002/biot.201300001.
[32] Tamura T, Hamachi I. Recent progress in design of protein-based fluorescent biosensors and their cellular applications. ACS Chem Biol. 2014 Dec 19;9(12):2708-17. doi: 10.1021/cb500661v.
[33] Singhvi P, Saneja A, Ahuja R, Panda AK. Solubilization and refolding of variety of inclusion body proteins using a novel formulation. Int J BiolMacromol. 2021 Dec 15;193(Pt B):2352-2364. doi: 10.1016/j.ijbiomac.2021.11.068.
[34] Dumon-Seignovert L, Cariot G, Vuillard L. The toxicity of recombinant proteins in Escherichia coli: a comparison of overexpression in BL21(DE3), C41(DE3), and C43(DE3). Protein Expr Purif. 2004 Sep;37(1):203-6. doi: 10.1016/j.pep.2004.04.025.
[35] Sisila V, Indhu M, Radhakrishnan J, Ayyadurai N. Building biomaterials through genetic code expansion. Trends Biotechnol. 2023 Feb;41(2):165-183. doi: 10.1016/j.tibtech.2022.07.003.
[36] Bastos PAD, da Costa JP, Vitorino R. A glimpse into the modulation of post-translational modifications of human-colonizing bacteria. J Proteomics. 2017 Jan 30;152:254-275. doi: 10.1016/j.jprot.2016.11.005.
[37] Hoffmann D, Ebrahimi M, Gerlach D, Salzig D, Czermak P. Reassessment of inclusion body-based production as a versatile opportunity for difficult-to-express recombinant proteins. Crit Rev Biotechnol. 2018 Aug;38(5):729-744. doi: 10.1080/07388551.2017.1398134.
[38] Rajacharya GH, Sharma A, Yazdani SS. Proteomics and metabolic burden analysis to understand the impact of recombinant protein production in E. coli. Sci Rep. 2024 May 28;14(1):12271. doi: 10.1038/s41598-024-63148-y.
[39] Patil R, Walther J. Continuous Manufacturing of Recombinant Therapeutic Proteins: Upstream and Downstream Technologies. Adv Biochem Eng Biotechnol. 2018;165:277-322. doi: 10.1007/10_2016_58.
[40] Mishra V. Affinity Tags for Protein Purification. Curr Protein Pept Sci. 2020;21(8):821-830. doi: 10.2174/1389203721666200606220109.
[41] Mattanovich D, Branduardi P, Dato L, Gasser B, Sauer M, Porro D. Recombinant protein production in yeasts. Methods Mol Biol. 2012;824:329-58. doi: 10.1007/978-1-61779-433-9_17.
[42] Schwarzer E, Skorokhod O. Post-Translational Modifications of Proteins of Malaria Parasites during the Life Cycle. Int J Mol Sci. 2024 Jun 2;25(11):6145. doi: 10.3390/ijms25116145.
[43] Fischer R, Schillberg S, Hellwig S, Twyman RM, Drossard J. GMP issues for recombinant plant-derived pharmaceutical proteins. Biotechnol Adv. 2012 Mar-Apr;30(2):434-9. doi: 10.1016/j.biotechadv.2011.08.007.

[44] Myhr AI. DNA Vaccines: Regulatory Considerations and Safety Aspects. Curr Issues Mol Biol. 2017;22:79-88. doi: 10.21775/cimb.022.079.
[45] Lu B, Lim JM, Yu B, Song S, Neeli P, Sobhani N, K P, Bonam SR, Kurapati R, Zheng J, Chai D. The next-generation DNA vaccine platforms and delivery systems: advances, challenges and prospects. Front Immunol. 2024 Feb 1;15:1332939. doi: 10.3389/fimmu.2024.1332939.
[46] Pandya A, Shah Y, Kothari N, Postwala H, Shah A, Parekh P, Chorawala MR. The future of cancer immunotherapy: DNA vaccines leading the way. Med Oncol. 2023 Jun 9;40(7):200. doi: 10.1007/s12032-023-02060-3.
[47] Saito Y, Kitagawa W, Kumagai T, Tajima N, Nishimiya Y, Tamano K, Yasutake Y, Tamura T, Kameda T. Developing a codon optimization method for improved expression of recombinant proteins in actinobacteria. Sci Rep. 2019 Jun 6;9(1):8338. doi: 10.1038/s41598-019-44500-z.
[48] Kosobokova EN, Skrypnik KA, Kosorukov VS. Overview of Fusion Tags for Recombinant Proteins. Biochemistry (Mosc). 2016 Mar;81(3):187-200. doi: 10.1134/S0006297916030019.
[49] Fatima K, Naqvi F, Younas H. A Review: Molecular Chaperone-mediated Folding, Unfolding and Disaggregation of Expressed Recombinant Proteins. Cell BiochemBiophys. 2021 Jun;79(2):153-174. doi: 10.1007/s12013-021-00970-5.
[50] Thak EJ, Yoo SJ, Moon HY, Kang HA. Yeast synthetic biology for designed cell factories producing secretory recombinant proteins. FEMS Yeast Res. 2020 Mar 1;20(2):foaa009. doi: 10.1093/femsyr/foaa009.
[51] Xue Z, Zeng J, Li Y, Meng B, Gong X, Zhao Y, Dai X. Proteomics reveals that cell density could affect the efficacy of drug treatment. BiochemBiophys Rep. 2022 Dec 9;33:101403. doi: 10.1016/j.bbrep.2022.101403.
[52] Buntru M, Vogel S, Finnern R, Schillberg S. Plant-Based Cell-Free Transcription and Translation of Recombinant Proteins. Methods Mol Biol. 2022;2480:113-124. doi: 10.1007/978-1-0716-2241-4_8.
[53] Matreyek KA, Stephany JJ, Chiasson MA, Hasle N, Fowler DM. An improved platform for functional assessment of large protein libraries in mammalian cells. Nucleic Acids Res. 2020 Jan 10;48(1):e1. doi: 10.1093/nar/gkz910.
[54] Lenneman BR, Fernbach J, Loessner MJ, Lu TK, Kilcher S. Enhancing phage therapy through synthetic biology and genome engineering. Curr OpinBiotechnol. 2021 Apr;68:151-159. doi: 10.1016/j.copbio.2020.11.003.
[55] Wang Y, Demirer GS. Synthetic biology for plant genetic engineering and molecular farming. Trends Biotechnol. 2023 Sep;41(9):1182-1198. doi: 10.1016/j.tibtech.2023.03.007.
[56] Gomase VS, Tripathi AK, Tagore S. Cellunomics: the interaction analysis of cells. Int J Bioinform Res Appl. 2009;5(6):674-90. doi: 10.1504/IJBRA.2009.029046.
[57] Casini A, Storch M, Baldwin GS, Ellis T. Bricks and blueprints: methods and standards for DNA assembly. Nat Rev Mol Cell Biol. 2015 Sep;16(9):568-76. doi: 10.1038/nrm4014.
[58] Wang SW, Gao C, Zheng YM, Yi L, Lu JC, Huang XY, Cai JB, Zhang PF, Cui YH, Ke AW. Current applications and future perspective of CRISPR/Cas9 gene editing in cancer. Mol Cancer. 2022 Feb 21;21(1):57. doi: 10.1186/s12943-022-01518-8.
[59] Shamshirgaran Y, Liu J, Sumer H, Verma PJ, Taheri-Ghahfarokhi A. Tools for Efficient Genome Editing; ZFN, TALEN, and CRISPR. Methods Mol Biol. 2022;2495:29-46. doi: 10.1007/978-1-0716-2301-5_2.

[60] Koo J. Cell-Free Protein Synthesis of Metalloproteins. Adv Biochem Eng Biotechnol. 2023;185:47-58. doi: 10.1007/10_2023_233.
[61] Aydin H, Azimi FC, Cook JD, Lee JE. A convenient and general expression platform for the production of secreted proteins from human cells. J Vis Exp. 2012 Jul 31;(65):4041. doi: 10.3791/4041.
[62] Dörr M, Fibinger MP, Last D, Schmidt S, Santos-Aberturas J, Böttcher D, Hummel A, Vickers C, Voss M, Bornscheuer UT. Fully automatized high-throughput enzyme library screening using a robotic platform. BiotechnolBioeng. 2016 Jul;113(7):1421-32. doi: 10.1002/bit.25925.
[63] Lee J, Campillo B, Hamidian S, Liu Z, Shorey M, St-Pierre F. Automating the High-Throughput Screening of Protein-Based Optical Indicators and Actuators. Biochemistry. 2023 Jan 17;62(2):169-177. doi: 10.1021/acs.biochem.2c00357.
[64] Priola JJ, Calzadilla N, Baumann M, Borth N, Tate CG, Betenbaugh MJ. High-throughput screening and selection of mammalian cells for enhanced protein production. Biotechnol J. 2016 Jul;11(7):853-65. doi: 10.1002/biot.201500579.
[65] Gomase VS, Tagore S, Changbhale SS, Kale KV. Pharmacogenomics. Curr Drug Metab. 2008 Mar;9(3):207-12. doi: 10.2174/138920008783884830.
[66] Kontoyianni M. Docking and Virtual Screening in Drug Discovery. Methods Mol Biol. 2017;1647:255-266. doi: 10.1007/978-1-4939-7201-2_18.
[67] Büssow K, Nordhoff E, Lübbert C, Lehrach H, Walter G. A human cDNA library for high-throughput protein expression screening. Genomics. 2000 Apr 1;65(1):1-8. doi: 10.1006/geno.2000.6141.
[68] 68 Li Y. Self-cleaving fusion tags for recombinant protein production. Biotechnol Lett. 2011 May;33(5):869-81. doi: 10.1007/s10529-011-0533-8.
[69] Spriestersbach A, Kubicek J, Schäfer F, Block H, Maertens B. Purification of His-Tagged Proteins. Methods Enzymol. 2015;559:1-15. doi: 10.1016/bs.mie.2014.11.003.
[70] Ollier R, Wassmann P, Monney T, Ries Fecourt C, Gn S, C A V, Ayoub D, Stutz C, Gudi GS, Blein S. Single-step Protein A and Protein G avidity purification methods to support bispecific antibody discovery and development. MAbs. 2019 Nov-Dec;11(8):1464-1478. doi: 10.1080/19420862.2019.1660564.
[71] Stulz R, Lerche M, Luige O, Taylor A, Geschwindner S, Ghidini A. An enhanced biophysical screening strategy to investigate the affinity of ASOs for their target RNA. RSC Chem Biol. 2023 Oct 23;4(12):1123-1130. doi: 10.1039/d3cb00072a.
[72] Gomase VS, Changbhale SS, Patil SA, Kale KV. Metabolomics. Curr Drug Metab. 2008 Jan;9(1):89-98. doi: 10.2174/138920008783331149.
[73] Tihanyi B, Nyitray L. Recent advances in CHO cell line development for recombinant protein production. Drug Discov Today Technol. 2020 Dec;38:25-34. doi: 10.1016/j.ddtec.2021.02.003. Epub 2021 Apr 12. PMID: 34895638.
[74] Singh R, Fatima E, Thakur L, Singh S, Ratan C, Kumar N. Advancements in CHO metabolomics: techniques, current state and evolving methodologies. Front BioengBiotechnol. 2024 Mar 27;12:1347138. doi: 10.3389/fbioe.2024.1347138.
[75] Coulet M, Kepp O, Kroemer G, Basmaciogullari S. Metabolic Profiling of CHO Cells during the Production of Biotherapeutics. Cells. 2022 Jun 15;11(12):1929. doi: 10.3390/cells11121929.
[76] Santero E, Díaz E. Special Issue: Genetics of Biodegradation and Bioremediation. Genes (Basel). 2020 Apr 17;11(4):441. doi: 10.3390/genes11040441.

[77] Maity W, Maity S, Bera S, Roy A. Emerging Roles of PETase and MHETase in the Biodegradation of Plastic Wastes. Appl BiochemBiotechnol. 2021 Aug;193(8):2699-2716. doi: 10.1007/s12010-021-03562-4.
[78] Patel AK, Singhania RR, Albarico FPJB, Pandey A, Chen CW, Dong CD. Organic wastes bioremediation and its changing prospects. Sci Total Environ. 2022 Jun 10;824:153889. doi: 10.1016/j.scitotenv.2022.153889.
[79] Swain R, Sahoo S, Behera M, Rout GR. Instigating prevalent abiotic stress resilience in crop by exogenous application of phytohormones and nutrient. Front Plant Sci. 2023 Feb 9;14:1104874. doi: 10.3389/fpls.2023.1104874.

[80] Goetz LH, Schork NJ. Personalized medicine: motivation, challenges, and progress. Fertil Steril. 2018 Jun;109(6):952-963. doi: 10.1016/j.fertnstert.2018.05.006.
[81] Braig ZV. Personalized medicine: From diagnostic to adaptive. Biomed J. 2022 Feb;45(1):132-142. doi: 10.1016/j.bj.2019.05.004.
[82] Choi D, Gonzalez-Suarez AM, Billadeau DD, Ma WW, Stybayeva G, Revzin A. Patient-Specific Microfluidic Cancer Spheroid Cultures for Testing Cancer Therapies. Methods Mol Biol. 2023;2679:219-231. doi: 10.1007/978-1-0716-3271-0_15.
[83] Aboulkheyr Es H, Montazeri L, Aref AR, Vosough M, Baharvand H. Personalized Cancer Medicine: An Organoid Approach. Trends Biotechnol. 2018 Apr;36(4):358-371. doi: 10.1016/j.tibtech.2017.12.005.
[84] Manickam P, Mariappan SA, Murugesan SM, Hansda S, Kaushik A, Shinde R, Thipperudraswamy SP. Artificial Intelligence (AI) and Internet of Medical Things (IoMT) Assisted Biomedical Systems for Intelligent Healthcare. Biosensors (Basel). 2022 Jul 25;12(8):562. doi: 10.3390/bios12080562.
[85] Taha BA, Al Mashhadany Y, Al-Jubouri Q, Rashid ARBA, Luo Y, Chen Z, Rustagi S, Chaudhary V, Arsad N. Next-generation nanophotonic-enabled biosensors for intelligent diagnosis of SARS-CoV-2 variants. Sci Total Environ. 2023 Jul 1;880:163333. doi: 10.1016/j.scitotenv.2023.163333.
[86] Jain S, Nehra M, Kumar R, Dilbaghi N, Hu T, Kumar S, Kaushik A, Li CZ. Internet of medical things (IoMT)-integrated biosensors for point-of-care testing of infectious diseases. BiosensBioelectron. 2021 May 1;179:113074. doi: 10.1016/j.bios.2021.113074.
[87] Schito M, Migliori GB, Fletcher HA, McNerney R, Centis R, D'Ambrosio L, Bates M, Kibiki G, Kapata N, Corrah T, Bomanji J, Vilaplana C, Johnson D, Mwaba P, Maeurer M, Zumla A. Perspectives on Advances in Tuberculosis Diagnostics, Drugs, and Vaccines. Clin Infect Dis. 2015 Oct 15;61Suppl 3(Suppl 3):S102-18. doi: 10.1093/cid/civ609.
[88] Díaz-Gómez JL, Mayo PH, Koenig SJ. Point-of-Care Ultrasonography. N Engl J Med. 2021 Oct 21;385(17):1593-1602. doi: 10.1056/NEJMra1916062.
[89] Adamson PC, Loeffelholz MJ, Klausner JD. Point-of-Care Testing for Sexually Transmitted Infections: A Review of Recent Developments. Arch Pathol Lab Med. 2020 Nov 1;144(11):1344-1351. doi: 10.5858/arpa.2020-0118-RA.
[90] Shirai K, Yazawa M, Yoshida K, Shibagaki Y. Point-of-Care Ultrasound for the Diagnosis of Congestive Kidney Due to Severe Acidemia: A Case Report. Cureus. 2024 Mar 27;16(3):e57096. doi: 10.7759/cureus.57096.

Graphical Abstract